InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-04 | SATO VICKI L | Director | Sale | 22.0K | $10.05 | $221K | 1.08M | View ↗ | |
| 2026-04-06 | 2026-04-07 | De Backer Marianne | Director & President and CEO | Sale | 72.6K | $9.16 | $664K | 948.1K | View ↗ | |
| 2026-04-01 | 2026-04-02 | SATO VICKI L | Director | Sale | 22.0K | $9.07 | $200K | 1.10M | View ↗ | |
| 2026-03-23 | 2026-03-24 | Sabatini Brent | SVP, Chief Accounting Officer | Sale | 7,711 | $9.12 | $70K | 61.9K | View ↗ | |
| 2026-03-02 | 2026-03-03 | SATO VICKI L | Director | Sale | 22.0K | $9.51 | $209K | 1.12M | View ↗ |
| Agency | Amount |
|---|---|
| Department of Energy | $1.54B |
From USASpending.gov. Matched by company name keyword.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $3.4M-67.7% | $10.5M-77.5% | $46.7M+32.2% | $35.3M+323.2% | $8.3M |
| Cost of revenue | $26K-96.9% | $845K-69.4% | $2.8M-98.1% | $146.3M+122.1% | $65.9M |
| Research and development | $456.0M-10.0% | $506.5M-12.6% | $579.7M+22.1% | $474.6M+5.9% | $448.0M |
| Selling, general and administrative | $92.1M-22.6% | $119.0M-31.8% | $174.4M+7.8% | $161.8M+0.6% | $160.8M |
| Restructuring, long-lived assets impairment and related charges, net | -$182K-100.5% | $35.0M+158.1% | $13.6M | $0 | — |
| Total operating expenses | $547.9M-17.2% | $661.4M-14.2% | $770.5M-1.6% | $782.7M+16.0% | $674.7M |
| Loss from operations | -$479.3M+18.4% | -$587.2M+14.2% | -$684.3M-182.1% | $833.1M+98.0% | $420.8M |
| Change in fair value of equity investments | $1.7M+131.3% | -$5.5M+74.7% | -$21.9M+80.3% | -$111.1M-180.5% | $138.0M |
| Interest income | $40.2M-44.0% | $71.8M-17.5% | $87.0M+209.7% | $28.1M+6299.1% | $439K |
| Other expense, net | -$409K+81.6% | -$2.2M+75.3% | -$9.0M-311.1% | $4.3M+145.1% | -$9.4M |
| Total other income | $41.6M-35.1% | $64.1M+14.2% | $56.1M+171.2% | -$78.8M-161.1% | $129.1M |
| Loss before (provision for) benefit from income taxes | -$437.8M+16.3% | -$523.1M+16.7% | -$628.2M-183.3% | $754.3M+37.2% | $549.8M |
| (Provision for) benefit from income taxes | -$217K-119.0% | $1.1M-91.2% | $13.1M+105.5% | -$238.4M-1023.8% | -$21.2M |
| Net loss | -$438.0M+16.1% | -$522.0M+15.1% | -$615.1M-219.2% | $515.8M | — |
| Net loss attributable to noncontrolling interest | $0 | $0+100.0% | -$56K | $0 | $0 |
| Net loss attributable to Vir Bio | -$438.0M+16.1% | -$522.0M+15.1% | -$615.1M-219.2% | $515.8M-2.4% | $528.6M |
| Net loss per share attributable to VirBio, basic (in USD per share) | -$3K+17.5% | -$4K+16.6% | -$5K-218.0% | $4K+95477.4% | $4.07 |
| Net loss per share attributable to VirBio, diluted (in USD per share) | -$3K+17.5% | -$4K+16.6% | -$5K-219.8% | $4K+96617.2% | $3.96 |
| Weighted-average shares outstanding, basic (in shares) | $138.52B+1.7% | $136.25B+1.6% | $134.13B+1.1% | $132.61B+101995.5% | $129.9M |
| Weighted-average shares outstanding, diluted (in shares) | $138.52B+1.7% | $136.25B+1.6% | $134.13B-0.5% | $134.81B+100929.5% | $133.4M |
| License and collaboration revenue | |||||
| Grant revenue | |||||
| Other revenue | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million